Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
11 výsledky
Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
TECHNICAL FIELD
The present invention relates to a nitrogen-containing bicyclic compound or a pharmacologically acceptable salt thereof and a pharmaceutical composition comprising it as active ingredient.
More specifically, the present invention relates to (1) a compound of formula (I)
##STR00002##
Substituted benzopyrans as selective estrogen receptor-beta agonists
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
The present invention relates to novel benzopyran ER-.beta. agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-.beta. mediated disease such as benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon
Piperidine derivative compounds and drugs containing the compounds as the active ingredient
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
TECHNICAL FIELD
The present invention relates to a piperidine derivative.
More specifically, the present invention relates to (1) a piperidine derivative of formula (I)
##STR00002## (2) a method for the preparation thereof, (3) a composition comprising it as an active ingredient, (4) a compound of
LKB1-AMPK activators for therapeutic use in polycystic kidney disease
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND
Autosomal dominant polycystic kidney disease (ADPKD) is a frequently inherited kidney disorder with a gene frequency of 1 in 500 to 1,000 births affecting nearly 600,000 Americans and as many as 12 million people worldwide. This potentially lethal genetic disease is characterized by the
LKB1-AMPK activators for therapeutic use in polycystic kidney disease
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND
Autosomal dominant polycystic kidney disease (ADPKD) is a frequently inherited kidney disorder with a gene frequency of 1 in 500 to 1,000 births affecting nearly 600,000 Americans and as many as 12 million people worldwide. This potentially lethal genetic disease is characterized by the
Methods of screening for compounds which bind G protein-coupled receptors
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the 35 U.S.C. .sctn.371 national stage of PCT application PCT/JP2005/007354, filed Apr. 11, 2005, which claims priority to Japanese patent application No. 116725/2004, filed Apr. 12, 2004. The contents of these applications are incorporated
Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
FIELD OF THE INVENTION
The present invention relates to compounds which modulate one or more of ERalpha/beta and GPR30 receptors, to pharmaceutical compositions based upon those compounds and to methods of treating disease states and conditions mediated through these receptors and related methods
Compounds for binding to ER.alpha./.beta. and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
FIELD OF THE INVENTION
The present invention relates to compounds which modulate one or more of ERalpha/beta and GPR30 receptors, to pharmaceutical compositions based upon those compounds and to methods of treating disease states and conditions mediated through these receptors and related methods
Substituted tetralins as selective estrogen receptor-.beta. agonists
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND OF THE INVENTION
The present invention relates to novel tetralin ER-.beta. agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-.beta. mediated disease such as benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon
Piperidine derivatives and agent comprising the derivative as active ingredient
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
TECHNICAL FIELD
The present invention relates to piperidine derivatives.
More specifically, the present invention relates to
(1) piperidine derivatives represented by formula (I):
##STR00002## (wherein all symbols have the same meanings as described below), or nontoxic salts thereof, (2) a process
Piperidine derivatives and agent comprising the derivative as active ingredient
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
TECHNICAL FIELD
The present invention relates to piperidine derivatives.
More specifically, the present invention relates to (1) piperidine derivatives represented by formula (I):
##STR00002## (wherein all symbols have the same meanings as described below), or nontoxic salts thereof, (2) a process
Najkompletnejšia databáza liečivých bylín podporovaná vedou
- Pracuje v 55 jazykoch
- Bylinné lieky podporené vedou
- Rozpoznávanie bylín podľa obrázka
- Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
- Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
- Vyhľadajte liečivé byliny podľa ich účinkov
- Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi
Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume
